A meta-analysis published in The Journal of Nuclear Medicine indicates that amino acid PET can accurately differentiate recurrent or progressive brain metastases from treatment-related changes. A specificity of 84% suggests that it may reduce the number of invasive procedures and overtreatment in patients who in fact experience treatment-related changes.
Brain metastases occur in 20% to 40% of all cancer patients and are most likely to occur in those with lung, breast and renal cancer, melanoma, and cancers of the gastrointestinal tract. Management of patients with brain metastases usually includes surgery, radiation and chemotherapy. Some patients develop treatment-related changes such as radiation necrosis or pseudoprogression.
“A differentiation between recurrent or progressive brain metastases and treatment-related changes is challenging,” said Igor Yakushev, senior physician in the department of nuclear medicine at Technical University of Munich in Germany. “As the management of patients with recurrent or progressive brain metastases and treatment-related changes is fairly different, accurate and early differential diagnosis is essential.”
The meta-analysis included 12 studies with amino acid PET radiotracers. The studies included a total of 397 patients with 547 lesions. Overall, 269 lesions (49%) were found to be recurrent or progressive brain metastases. Using a histologic examination and/or radiological and clinical follow-up as reference, pooled sensitivity and specificity of amino acid PET were found to be 82% and 84% respectively.
“This study provides IIa class evidence on diagnostic utility of amino acid PET in the differential diagnosis of recurrent or progressive brain metastases,” stated Yakushev. “These findings are in line with an increasing role of molecular imaging in the management of patients with brain tumors, yet the results also point to potential for further improvement of diagnostic accuracy.”Back To Top
Amino Acid PET Differentiates Recurrent Brain Metastases From Treatment-Related Changes. Appl Rad Oncol.